The stock of Angiodynamic Inc (ANGO) has seen a 8.06% increase in the past week, with a 32.22% gain in the past month, and a 27.94% flourish in the past quarter. The volatility ratio for the week is 5.13%, and the volatility levels for the past 30 days are at 5.37% for ANGO. The simple moving average for the last 20 days is 19.08% for ANGO’s stock, with a simple moving average of 18.56% for the last 200 days.
Is It Worth Investing in Angiodynamic Inc (NASDAQ: ANGO) Right Now?
The 36-month beta value for ANGO is at 0.64. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ANGO is 38.21M, and currently, shorts hold a 4.43% of that float. The average trading volume for ANGO on July 26, 2024 was 512.85K shares.
ANGO) stock’s latest price update
Angiodynamic Inc (NASDAQ: ANGO)’s stock price has soared by 2.46 in relation to previous closing price of 7.33. Nevertheless, the company has seen a gain of 8.06% in its stock price over the last five trading days. seekingalpha.com reported 2024-07-17 that AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, AlphaVac, and NanoKnife all have legitimate growth potential, but significant competition as well.
Analysts’ Opinion of ANGO
Many brokerage firms have already submitted their reports for ANGO stocks, with Oppenheimer repeating the rating for ANGO by listing it as a “Outperform.” The predicted price for ANGO in the upcoming period, according to Oppenheimer is $12 based on the research report published on April 05, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ANGO reach a price target of $19. The rating they have provided for ANGO stocks is “Buy” according to the report published on September 25th, 2023.
Raymond James gave a rating of “Outperform” to ANGO, setting the target price at $13 in the report published on April 17th of the previous year.
ANGO Trading at 20.90% from the 50-Day Moving Average
After a stumble in the market that brought ANGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.36% of loss for the given period.
Volatility was left at 5.37%, however, over the last 30 days, the volatility rate increased by 5.13%, as shares surge +30.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.71% upper at present.
During the last 5 trading sessions, ANGO rose by +8.06%, which changed the moving average for the period of 200-days by +6.22% in comparison to the 20-day moving average, which settled at $6.39. In addition, Angiodynamic Inc saw -4.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANGO starting from Clemmer James C, who purchase 10,000 shares at the price of $6.70 back on Apr 08 ’24. After this action, Clemmer James C now owns 539,066 shares of Angiodynamic Inc, valued at $67,000 using the latest closing price.
Stock Fundamentals for ANGO
Current profitability levels for the company are sitting at:
- 0.01 for the present operating margin
- 0.49 for the gross margin
The net margin for Angiodynamic Inc stands at -0.61. The total capital return value is set at 0.02. Equity return is now at value -63.15, with -43.36 for asset returns.
Currently, EBITDA for the company is -6.13 million with net debt to EBITDA at 1.71. When we switch over and look at the enterprise to sales, we see a ratio of 0.74. The receivables turnover for the company is 6.97for trailing twelve months and the total asset turnover is 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
In conclusion, Angiodynamic Inc (ANGO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
